2026年 플레너리 프로그램(기조 강연)

Discovery on Target의 플레너리 프로그램(기조 강연)에 전 세계의 동료들과 함께 참가해 주십시오. Drug Discovery 전문가들로 구성된 DOT 커뮤니티 전체가 한자리에 모여 이 분야의 전문가로부터 거시적인 시점 및 혁신적인 기술, 그리고 깊은 통찰을 주는 동향에 대해 배울 수 있습니다.

Tuesday, September 29 | 4:50-6:05 pm

OPENING PLENARY KEYNOTE PANEL

Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach
This panel brings together senior leaders from pharma and biotech to explore how a modality-agnostic strategy is enabling progress against difficult yet high-value drug targets. Panelists will highlight how emerging modalities-from chimeras and conjugates to peptides and radioligands-along with ability to leverage technology innovations is shaping drug discovery and redefining what is now druggable.

PANEL MODERATOR:
Dennis Hu, PhD, CEO, Drug Hunter Inc.

PANELISTS:
Erin Davis, PhD, Vice President, Research Business Insights & Technology, Bristol Myers Squibb
Ryan Potts, PhD, VP and Head, Induced Proximity Platform, Amgen, Inc.
John Tallarico, PhD, Global Head, Discovery Sciences, Novartis BioMedical Research
Klaus Urbahns, PhD, Head, Therapeutic Modalities, Biogen
Andrea Weston, PhD, Head of Discovery Biology and Pharmacology, Pfizer Inc.
Ian Storer, PhD, VP, Hit Discovery, AstraZeneca

Wednesday, September 30 | 4:20-5:20 pm

INSIGHTS FROM VENTURE CAPITALISTS

Venture-Capitalist Insights on Trends in Drug Discovery
Panelists representing the investor ecosystem - venture capital, private equity, venture arms of pharmaceutical companies- share their thoughts and experiences working with a vast number of early and late-stage biotechnology companies and academic labs. They highlight current trends in investments for drug discovery and anticipated changes. This discussion also provides scientists an understanding of how investment strategy works and how they can secure the right funding to bring their ideas from the lab to market. There will be additional time for attendees to meet with the panelists after the session.

PANEL MODERATOR:
Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation

PANELISTS:
Chris De Savi, PhD, CSO Partner, Curie Bio
Neil Kubica, PhD, Therapeutics Division Lead, General Inception
Pengpeng Li, PhD, Principal, Lilly Asia Ventures
Ken Lin, CEO & Founder, ABIES Capital
Hok Hei Tam, PhD, Co-Founder and CTO, Montai Therapeutics; Science Partner, Flagship Pioneering

Thursday, October 1 | 1:35-3:00 pm

CLOSING PLENARY KEYNOTE PANEL

Starting Up: Translating Lab Ideas into Commercial Impact
This panel discussion brings together scientists from academia and biotech to share their stories on what it takes to translate transformative ideas into meaningful commercial outcomes. Panelists will delve into some of the critical inflection points, challenges encountered, key decisions that had to be made and their outcomes. The session will provide scientists with an understanding of what it takes to bring ideas from lab to market. There will be a dedicated time for attendees to have informal conversations with the panelists before the session begins.

PANEL MODERATOR:
Armon Sharei, PhD, Founder & CEO, Portal Biotechnologies

PANELISTS:
Sangeeta N. Bhatia, Professor, Director Marble Center for Cancer Nanomedicine, Health Sciences & Technology, Massachusetts Institute of Technology
Ivan Cornella Taracido, PhD, Founder, New Stealth Co.
Kris Elverum, MBA, Former President & CEO, AIRNA
Parastoo Khoshakhlagh, PhD, Co-Founder & CEO, GC Therapeutics
William Pao, MD, PhD, CEO, Revelio Therapeutics
Johnny Yu, PhD, CSO & Co-Founder, Tahoe Therapeutics